It’s been nearly three months since Anderson Silva and Nick Diaz failing UFC 183 related drug tests became public, but both fighters have yet to answer for their infractions before the Nevada Athletic Commission.
It will likely be May, at the soonest, that either will go before the commission to address his positive drug test results, according to the commission’s executive director Bob Bennett.
Bennett on Thursday confirmed to MMAWeekly.com that not only had Silva, as initially reported by Globo.com, requested and been granted a continuance, but so had Diaz. That means that both men have further time to respond to the commission’s complaint informing them of their drug test infractions, so that neither will have to appear at the commission’s regularly scheduled April 21 meeting to answer the charges.
Silva and Diaz both face disciplinary hearings before the commission stemming from the failed drug tests related to the UFC 183 headlining bout, which took place on Jan. 31 in Las Vegas.
Silva failed two drug tests. The first time he tested positive was in a Jan. 9 out-of-competition drug test, where his results revealed anabolic steroid metabolites for Drostanolone and Androstane.
After testing clean in a Jan. 19 out-of-competition test, Silva then again tested positive for Drostanolone, in addition to Oxazepam and Temazepam, two benzodiazepine class drugs commonly used to treat anxiety-related insomnia in his fight-night drug test.
Silva has never before tested positive for banned substances during his near-twenty-year career.
Diaz is required to go before the commission for testing positive for marijuana metabolites in his fight-night drug test.